ClinicalTrials.gg
CompletedNCT05107115RILECSUUpdated Aug 6, 2026Results posted

Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine

A Phase 2 interventional study of rilzabrutinib and placebo in Chronic Spontaneous Urticaria, sponsored by Sanofi. Completed at 128 sites in 13 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Chronic Urticaria with a site in Poland — 4 open to participants now, 9 under way, 6 of them phase 3. Chronic Urticaria · Poland.

Enrollment
19th of 28
160 · median 270
Started
2021
with 2 others
Phase 2
14 of 28
3 open now
Registered
14th of 28
by date

Among the 28 studies in Chronic Urticaria with a site in Poland, this one is the 19th largest by enrollment, is one of 3 that started in 2021, is one of 14 in phase 2, and was the 14th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

4 of the 28 studies in Chronic Urticaria with a site in Poland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Chronic Urticaria with a site in Poland, or all of them as a file.
02

Study summary

The first phase of this study will be a parallel, 12-week treatment, Phase 2, double-blind, 4 arm study to assess the safety and effectiveness of 3 oral doses of SAR444671 (rilzabrutinib), i.e. dose A, B and C, compared with placebo for decreasing the frequency and severity of itch and urticaria in male and female participants aged 18 years inclusive or older with CSU.

After completion of the double-blind phase of the study, participants will be given the option of enrolling in the 40-week open label extension (OLE) phase of the study. Participants will receive open-label rilzabrutinib at dose B or dose C (the dose may be modified based on the 12-week safety and efficacy data). Due to the fact that some participants may be receiving rilzabrutinib for the first time, all participants will be monitored at Week 14, Week 16, Week 20, and Week 24. Afterwards, participants will be monitored at Week 36 and Week 52.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who had a diagnosis of CSU to H1-AH at the time of randomization
  • Diagnosis of CSU ≥3 months prior to screening visit (Visit 1).
  • The presence of itch and hives for ≥6 consecutive weeks at any time prior to screening visit (Visit 1) despite the use of H1-AH during this time period.
  • Participants using a study defined H1-AH for CSU treatment. For participants on stable doses of non-study-approved H1-AH, investigators may switch participants to an equivalent dose of a study-approved H1-AH maintenance medication.
  • Participants who were omalizumab naïve OR omalizumab-incomplete responders.
  • Participants must be willing and able to complete a daily symptom e-diary for the duration of the study.
  • During the 7 days before randomization: UAS7 ≥16 and ISS7 ≥8.
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Clearly defined underlying etiology for CUs other than CSU (main manifestation being physical urticaria).
  • Presence of skin morbidities other than CSU that may interfere with the assessment of the study outcomes.
  • Participants with active atopic dermatitis (AD).
  • Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the patient's participation in the study.
  • Known or suspected immunodeficiency, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune compromised status, as judged by the Investigator.
  • History of serious infections requiring intravenous (IV) therapy with the potential for recurrence (as judged by the Site Investigator) with less than 4 weeks interval between resolution of serious infection and first dose of study drug, or currently active moderate to severe infection at Screening (Grade 2 or higher), including active coronavirus disease 2019 (COVID-19).
  • except Bacille Calmette Guerin-vaccination within 28 days prior to Day 1 or plan to receive one during the trial; Bacille Calmette Guerin-vaccination within 12 months prior to Screening.
  • Active or history of malignancy within 5 years.
  • Conditions that may predispose the participant to excessive bleeding
  • Any participant with an uncontrolled disease state as judged by the Investigator, such as asthma, psoriasis, or inflammatory bowel disease, etc. that are typically treated with oral or parenteral
  • Previous use of a BTK inhibitor.
  • Had received any drug (or is currently using an investigational device) within the 30 days before Day 1, or at least 5 times the respective elimination half-life time (whichever is longer).
  • Previous exposure to another investigative drug for CSU.
  • Positive for (HIV) antibody test.
  • Presence of surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with positive DNA test result at screening or within 3 months prior to the screening visit.
  • Positive antibody test result at screening or within 3 months prior to the screening visit.
  • Tuberculosis infection.
  • Any of significant laboratory abnormalities and findings at the screening visit.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Rilzabrutinib dose A

    dose A

    Drug: rilzabrutinib

  • Experimental
    Rilzabrutinib dose B

    dose B

    Drug: rilzabrutinib

  • Experimental
    Rilzabrutinib dose C

    dose C

    Drug: rilzabrutinib

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: placebo

Interventions

  • Tablet, oral use

    Also known as: PRN1008/SAR444671

  • Drugplacebo

    Tablet, oral use

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12

    The UAS7 score is a composite score containing both the hive severity score (HSS, ranging from 0 = None to 3 = more than 50 hives) and the itch severity score (ISS, ranging from 0 = None to 3 = intense). The daily UAS scores ranged from 0 to 6 points per day. Daily UAS scores were summed over a 7-day period to create the UAS7, ranging from 0 to 42, and are composed of the HSS7 and ISS7 components. A higher score indicates worse disease. Baseline is defined as the sum of the 7 days measurements obtained on and prior to the target visit day.

    Time frame: Baseline and Week 12

  2. Change From Baseline in Weekly Itch Severity Score (ISS7) at Week 12

    The ISS represents the itch severity on a scale and was recorded by the participant in their e-diary ranging from 0 (None) to 3 (intense). The ISS7 is the sum of ISS for the previous 7 days. The ISS7 represents itch severity on a scale ranging from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of itch. Baseline is defined as the sum of the 7 days measurements obtained on and prior to the target visit day.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in Weekly Urticaria Activity Score at Week 4

    The UAS7 score is a composite score containing both the hive severity score (HSS, ranging from 0 = None to 3 = more than 50 hives) and the itch severity score (ISS, ranging from 0 = None to 3 = intense). The daily UAS scores ranged from 0 to 6 points per day. Daily UAS scores were summed over a 7-day period to create the UAS7, ranging from 0 to 42, and are composed of the HSS7 and ISS7 components. A higher score indicates worse disease. Baseline is defined as the sum of the 7 measurements obtained within the 7 days prior to randomization.

    Time frame: Baseline and Week 4

  2. Change From Baseline in Weekly Hives Severity Score (HSS7) at Week 12

    The HSS7 represents hive severity score on a scale recorded on e-diary ranging from 0 (None) to 3 (more than 50 hives). A weekly score (HSS7) was sum of the average daily scores of the previous 7 days. The possible range of the weekly score was 0-21 (highest hives activity). Baseline is defined as the sum of the 7 days measurements obtained on and prior to the target visit day.

    Time frame: Baseline and Week 12

  3. Percentage of Participants With Weekly Urticaria Activity Score Less Than or Equal to (≤)6 at Week 12

    The UAS7 score is a composite score containing both the hive severity score (HSS, ranging from 0 = None to 3 = more than 50 hives) and the itch severity score (ISS, ranging from 0 = None to 3 = intense). The daily UAS scores ranged from 0 to 6 points per day. Daily UAS scores were summed over a 7-day period to create the UAS7, ranging from 0 to 42, and are composed of the HSS7 and ISS7 components. A higher score indicates worse disease. Here, a score ≤6 indicates well-controlled disease.

    Time frame: At Week 12

  4. Percentage of Participants With Weekly Urticaria Activity Score Equal to 0 at Week 12

    The UAS7 score is a composite score containing both the hive severity score (HSS, ranging from 0 = None to 3 = more than 50 hives) and the itch severity score (ISS, ranging from 0 = None to 3 = intense). The daily UAS scores ranged from 0 to 6 points per day. Daily UAS scores were summed over a 7-day period to create the UAS7, ranging from 0 to 42, and are composed of the HSS7 and ISS7 components. A higher score indicates worse disease. Here, score 0 indicates an absence of both itches and hives and a complete resolution of chronic spontaneous urticaria (CSU) symptoms.

    Time frame: At Week 12

  5. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Treatment-Emergent Adverse Events of Special Interest (AESIs), and Withdrawals Due to Treatment-Emergent Adverse Events

    Adverse event (AE): any untoward medical occurrence in participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs: AEs that developed or worsened or became serious during treatment-emergent period, defined as time from first administration of study treatment (on Day 1) to last administration of study treatment + 7 days. SAE: any AE that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was a medically important event. An AESI was an TEAE (serious or nonserious) of scientific and medical concern specific to Sponsor's product or program.

    Time frame: From first dose of study treatment (Day 1) up to last dose of study treatment + 7 days, approximately 13 weeks for DB period and approximately 41 weeks for OLE period

  6. Plasma Concentration of Rilzabrutinib

    Plasma samples were collected at specified timepoints for evaluation of rilzabrutinib pharmacokinetic (PK) concentrations.

    Time frame: Pre-dose and 2 hours post-dose at Day 1 and Week 4; pre-dose at Week 12 (DB period); pre-dose and 2 hours post-dose at Week 16; pre-dose at Weeks 20, 24 and 52 (OLE period)

07

Results

Posted Aug 6, 2026

Participant flow

The study was conducted at 59 active centers in 13 countries. A total of 240 participants were screened between 24 November 2021 and 28 February 2023, of which 80 were screen failures. Screen failures were mainly due to not meeting the eligibility criteria.

Double-Blind Period (Up to 12 Weeks)
Participant flow — Double-Blind Period (Up to 12 Weeks)
MilestoneDB Period: Placebo TIDDB Period: Rilzabrutinib 400 mg QPM + PlaceboDB Period: Rilzabrutinib 400 mg BID + PlaceboDB Period: Rilzabrutinib 400 mg TIDOLE Period: Rilzabrutinib 400 mg BIDOLE Period: Rilzabrutinib 400 mg TID
Started4038414100
Completed3734353600
Not completed346500
Withdrew: Other010000
Withdrew: Withdrawal by subject324400
Withdrew: Poor compliance to protocol011000
Withdrew: Adverse event001100
OLE Period (Weeks 13 to 52: 40 Weeks)
Participant flow — OLE Period (Weeks 13 to 52: 40 Weeks)
MilestoneDB Period: Placebo TIDDB Period: Rilzabrutinib 400 mg QPM + PlaceboDB Period: Rilzabrutinib 400 mg BID + PlaceboDB Period: Rilzabrutinib 400 mg TIDOLE Period: Rilzabrutinib 400 mg BIDOLE Period: Rilzabrutinib 400 mg TID
Started00009128
Completed0000698
Not completed0000330
Withdrew: Other000003
Withdrew: Withdrawal by subject0000317
Withdrew: Poor compliance to protocol000001
Withdrew: Lack of efficacy000002
Withdrew: Adverse event000007

Outcome measures

PrimaryChange From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12

The UAS7 score is a composite score containing both the hive severity score (HSS, ranging from 0 = None to 3 = more than 50 hives) and the itch severity score (ISS, ranging from 0 = None to 3 = intense). The daily UAS scores ranged from 0 to 6 points per day. Daily UAS scores were summed over a 7-day period to create the UAS7, ranging from 0 to 42, and are composed of the HSS7 and ISS7 components. A higher score indicates worse disease. Baseline is defined as the sum of the 7 days measurements obtained on and prior to the target visit day.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12
score on a scaleDB Period: Placebo TIDDB Period: Rilzabrutinib 400 mg QPM + PlaceboDB Period: Rilzabrutinib 400 mg BID + PlaceboDB Period: Rilzabrutinib 400 mg TID
Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12-10.14 ± 2.05-9.74 ± 2.00-14.24 ± 2.06-16.89 ± 2.04
Statistical analysis
  • DB Period: Placebo TID vs DB Period: Rilzabrutinib 400 mg QPM + Placebo · ANCOVA · p = 0.8856 · Least square (ls) mean difference: 0.40 · 95% CI -5.08 to 5.89
  • DB Period: Placebo TID vs DB Period: Rilzabrutinib 400 mg BID + Placebo · ANCOVA · p = 0.1441 · Ls mean difference: -4.09 · 95% CI -9.59 to 1.40
  • DB Period: Placebo TID vs DB Period: Rilzabrutinib 400 mg TID · ANCOVA · p = 0.0159 · Ls mean difference: -6.75 · 95% CI -12.23 to -1.26
PrimaryChange From Baseline in Weekly Itch Severity Score (ISS7) at Week 12

The ISS represents the itch severity on a scale and was recorded by the participant in their e-diary ranging from 0 (None) to 3 (intense). The ISS7 is the sum of ISS for the previous 7 days. The ISS7 represents itch severity on a scale ranging from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of itch. Baseline is defined as the sum of the 7 days measurements obtained on and prior to the target visit day.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Weekly Itch Severity Score (ISS7) at Week 12
score on a scaleDB Period: Placebo TIDDB Period: Rilzabrutinib 400 mg QPM + PlaceboDB Period: Rilzabrutinib 400 mg BID + PlaceboDB Period: Rilzabrutinib 400 mg TID
Change From Baseline in Weekly Itch Severity Score (ISS7) at Week 12-5.77 ± 1.05-5.19 ± 1.02-7.73 ± 1.06-9.21 ± 1.05
Statistical analysis
  • DB Period: Placebo TID vs DB Period: Rilzabrutinib 400 mg QPM + Placebo · ANCOVA · p = 0.6869 · Ls mean difference: 0.58 · 95% CI -2.24 to 3.40
  • DB Period: Placebo TID vs DB Period: Rilzabrutinib 400 mg BID + Placebo · ANCOVA · p = 0.1728 · Ls mean difference: -1.96 · 95% CI -4.77 to 0.86
  • DB Period: Placebo TID vs DB Period: Rilzabrutinib 400 mg TID · ANCOVA · p = 0.0168 · Ls mean difference: -3.44 · 95% CI -6.25 to -0.62
SecondaryChange From Baseline in Weekly Urticaria Activity Score at Week 4

The UAS7 score is a composite score containing both the hive severity score (HSS, ranging from 0 = None to 3 = more than 50 hives) and the itch severity score (ISS, ranging from 0 = None to 3 = intense). The daily UAS scores ranged from 0 to 6 points per day. Daily UAS scores were summed over a 7-day period to create the UAS7, ranging from 0 to 42, and are composed of the HSS7 and ISS7 components. A higher score indicates worse disease. Baseline is defined as the sum of the 7 measurements obtained within the 7 days prior to randomization.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · score on a scale
Change From Baseline in Weekly Urticaria Activity Score at Week 4
score on a scaleDB Period: Placebo TIDDB Period: Rilzabrutinib 400 mg QPM + PlaceboDB Period: Rilzabrutinib 400 mg BID + PlaceboDB Period: Rilzabrutinib 400 mg TID
Change From Baseline in Weekly Urticaria Activity Score at Week 4-7.06 ± 1.72-9.14 ± 1.66-12.89 ± 1.73-13.66 ± 1.72
SecondaryChange From Baseline in Weekly Hives Severity Score (HSS7) at Week 12

The HSS7 represents hive severity score on a scale recorded on e-diary ranging from 0 (None) to 3 (more than 50 hives). A weekly score (HSS7) was sum of the average daily scores of the previous 7 days. The possible range of the weekly score was 0-21 (highest hives activity). Baseline is defined as the sum of the 7 days measurements obtained on and prior to the target visit day.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Weekly Hives Severity Score (HSS7) at Week 12
score on a scaleDB Period: Placebo TIDDB Period: Rilzabrutinib 400 mg QPM + PlaceboDB Period: Rilzabrutinib 400 mg BID + PlaceboDB Period: Rilzabrutinib 400 mg TID
Change From Baseline in Weekly Hives Severity Score (HSS7) at Week 12-4.40 ± 1.06-4.49 ± 1.04-6.52 ± 1.07-7.64 ± 1.06
SecondaryPercentage of Participants With Weekly Urticaria Activity Score Less Than or Equal to (≤)6 at Week 12

The UAS7 score is a composite score containing both the hive severity score (HSS, ranging from 0 = None to 3 = more than 50 hives) and the itch severity score (ISS, ranging from 0 = None to 3 = intense). The daily UAS scores ranged from 0 to 6 points per day. Daily UAS scores were summed over a 7-day period to create the UAS7, ranging from 0 to 42, and are composed of the HSS7 and ISS7 components. A higher score indicates worse disease. Here, a score ≤6 indicates well-controlled disease.

Time frame:
At Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Weekly Urticaria Activity Score Less Than or Equal to (≤)6 at Week 12
percentage of participantsDB Period: Placebo TIDDB Period: Rilzabrutinib 400 mg QPM + PlaceboDB Period: Rilzabrutinib 400 mg BID + PlaceboDB Period: Rilzabrutinib 400 mg TID
Percentage of Participants With Weekly Urticaria Activity Score Less Than or Equal to (≤)6 at Week 1211.15.420.034.3
SecondaryPercentage of Participants With Weekly Urticaria Activity Score Equal to 0 at Week 12

The UAS7 score is a composite score containing both the hive severity score (HSS, ranging from 0 = None to 3 = more than 50 hives) and the itch severity score (ISS, ranging from 0 = None to 3 = intense). The daily UAS scores ranged from 0 to 6 points per day. Daily UAS scores were summed over a 7-day period to create the UAS7, ranging from 0 to 42, and are composed of the HSS7 and ISS7 components. A higher score indicates worse disease. Here, score 0 indicates an absence of both itches and hives and a complete resolution of chronic spontaneous urticaria (CSU) symptoms.

Time frame:
At Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Weekly Urticaria Activity Score Equal to 0 at Week 12
percentage of participantsDB Period: Placebo TIDDB Period: Rilzabrutinib 400 mg QPM + PlaceboDB Period: Rilzabrutinib 400 mg BID + PlaceboDB Period: Rilzabrutinib 400 mg TID
Percentage of Participants With Weekly Urticaria Activity Score Equal to 0 at Week 1211.12.714.320.0
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Treatment-Emergent Adverse Events of Special Interest (AESIs), and Withdrawals Due to Treatment-Emergent Adverse Events

Adverse event (AE): any untoward medical occurrence in participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs: AEs that developed or worsened or became serious during treatment-emergent period, defined as time from first administration of study treatment (on Day 1) to last administration of study treatment + 7 days. SAE: any AE that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was a medically important event. An AESI was an TEAE (serious or nonserious) of scientific and medical concern specific to Sponsor's product or program.

Time frame:
From first dose of study treatment (Day 1) up to last dose of study treatment + 7 days, approximately 13 weeks for DB period and approximately 41 weeks for OLE period
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Treatment-Emergent Adverse Events of Special Interest (AESIs), and Withdrawals Due to Treatment-Emergent Adverse Events
ParticipantsDB Period: Placebo TIDDB Period: Rilzabrutinib 400 mg QPM + PlaceboDB Period: Rilzabrutinib 400 mg BID + PlaceboDB Period: Rilzabrutinib 400 mg TIDOLE Period: Rilzabrutinib 400 mg BIDOLE Period: Rilzabrutinib 400 mg TID
TEAEs23233031789
TESAEs100214
Treatment-Emergent AESIs244345
Withdrawals due to TEAEs001106
SecondaryPlasma Concentration of Rilzabrutinib

Plasma samples were collected at specified timepoints for evaluation of rilzabrutinib pharmacokinetic (PK) concentrations.

Time frame:
Pre-dose and 2 hours post-dose at Day 1 and Week 4; pre-dose at Week 12 (DB period); pre-dose and 2 hours post-dose at Week 16; pre-dose at Weeks 20, 24 and 52 (OLE period)
Reported as:
Mean · nanogram per milliliter (ng/mL)
Plasma Concentration of Rilzabrutinib
nanogram per milliliter (ng/mL)DB Period: Rilzabrutinib 400 mg QPMDB Period: Rilzabrutinib 400 mg BIDDB Period: Rilzabrutinib 400 mg TIDOLE Period: Rilzabrutinib 400 mg BIDOLE Period: Rilzabrutinib 400 mg TID
Day 1: pre-dose0.00 ± 0.000.00 ± 0.000.00 ± 0.00——
Day 1: 2 hours post-dose1.43 ± 8.49133.77 ± 113.67181.16 ± 139.41——
Week 4: pre-dose13.83 ± 26.4026.46 ± 62.9527.73 ± 67.72——
Week 4: 2 hours post-dose5.63 ± 9.60186.40 ± 122.19266.13 ± 232.15——
Week 12: pre-dose5.68 ± 7.7911.83 ± 18.8025.18 ± 76.01——
Week 16: pre-dose———2.49 ± 1.6624.90 ± 44.17
Week 16: 2 hours post-dose———153.22 ± 145.99236.47 ± 204.47
Week 20: pre-dose———1.97 ± 0.8234.85 ± 83.79
Week 24: pre-dose———3.31 ± 1.4016.01 ± 29.32
Week 52: pre-dose———3.51 ± 1.9620.77 ± 39.33

Adverse events

Collected over Adverse events data were collected from first dose of study treatment (Day 1) up to last dose of study treatment + 7 days approximately 13 weeks for DB period and approximately 41 weeks for OLE period. All-cause mortality (death) was assessed from the signing of the ICF up to approximately 125 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Period: Placebo TID0/40 (0%)1/40 (2.5%)14/40 (35%)
DB Period: Rilzabrutinib 400 mg QPM + Placebo0/38 (0%)0/38 (0%)20/38 (52.6%)
DB Period: Rilzabrutinib 400 mg BID + Placebo0/41 (0%)0/41 (0%)26/41 (63.4%)
DB Period: Rilzabrutinib 400 mg TID0/41 (0%)2/41 (4.9%)25/41 (61%)
OLE Period: Rilzabrutinib 400 mg BID0/9 (0%)1/9 (11.1%)7/9 (77.8%)
OLE Period: Rilzabrutinib 400 mg TID0/128 (0%)4/128 (3.1%)59/128 (46.1%)
Most frequent serious events
Most frequent serious events
EventDB Period: Placebo TIDDB Period: Rilzabrutinib 400 mg QPM + PlaceboDB Period: Rilzabrutinib 400 mg BID + PlaceboDB Period: Rilzabrutinib 400 mg TIDOLE Period: Rilzabrutinib 400 mg BIDOLE Period: Rilzabrutinib 400 mg TID
Joint DislocationInjury, poisoning and procedural complications0/400/380/410/411/90/128
Ligament RuptureInjury, poisoning and procedural complications0/400/380/410/411/90/128
Peritonsillar AbscessInfections and infestations1/400/380/410/410/90/128
UrticariaSkin and subcutaneous tissue disorders0/400/380/411/410/91/128
Iatrogenic InjuryInjury, poisoning and procedural complications0/400/380/411/410/90/128
Viral Upper Respiratory Tract InfectionInfections and infestations0/400/380/410/410/91/128
Anaphylactic ShockImmune system disorders0/400/380/410/410/91/128
Vogt-Koyanagi-Harada DiseaseEye disorders0/400/380/410/410/91/128
Most frequent other events
Showing 10 of 33
Most frequent other events
EventDB Period: Placebo TIDDB Period: Rilzabrutinib 400 mg QPM + PlaceboDB Period: Rilzabrutinib 400 mg BID + PlaceboDB Period: Rilzabrutinib 400 mg TIDOLE Period: Rilzabrutinib 400 mg BIDOLE Period: Rilzabrutinib 400 mg TID
Covid-19Infections and infestations2/402/384/412/413/92/128
NasopharyngitisInfections and infestations2/401/381/412/413/99/128
DiarrhoeaGastrointestinal disorders6/403/3812/4112/411/919/128
NauseaGastrointestinal disorders2/405/387/418/411/917/128
HeadacheNervous system disorders0/402/386/414/410/97/128
Abdominal PainGastrointestinal disorders2/401/385/410/411/95/128
SinusitisInfections and infestations0/400/381/410/411/91/128
Vulvovaginal CandidiasisInfections and infestations0/400/380/410/411/91/128
LymphopeniaBlood and lymphatic system disorders0/400/380/410/411/90/128
Decreased AppetiteMetabolism and nutrition disorders0/400/380/411/411/90/128

Baseline characteristics

The randomized population consisted of all participants from screened population (who signed the informed consent form \[ICF\]) and had been allocated to a randomized study treatment by interactive response technology (IRT), regardless of whether the study treatment was received.

Age, Continuous
Age, Continuous(years)DB Period: Placebo TIDDB Period: Rilzabrutinib 400 mg QPM + PlaceboDB Period: Rilzabrutinib 400 mg BID + PlaceboDB Period: Rilzabrutinib 400 mg TIDTotal
Mean40.2 ± 14.042.1 ± 12.745.5 ± 13.448.5 ± 12.244.1 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)DB Period: Placebo TIDDB Period: Rilzabrutinib 400 mg QPM + PlaceboDB Period: Rilzabrutinib 400 mg BID + PlaceboDB Period: Rilzabrutinib 400 mg TIDTotal
Female26282533112
Male141016848
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DB Period: Placebo TIDDB Period: Rilzabrutinib 400 mg QPM + PlaceboDB Period: Rilzabrutinib 400 mg BID + PlaceboDB Period: Rilzabrutinib 400 mg TIDTotal
American Indian or Alaska Native00011
Asian91181038
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White31273330121
More than one race00000
Unknown or Not Reported00000
Weekly Urticaria Activity Score (UAS7)
Weekly Urticaria Activity Score (UAS7)(score on a scale)DB Period: Placebo TIDDB Period: Rilzabrutinib 400 mg QPM + PlaceboDB Period: Rilzabrutinib 400 mg BID + PlaceboDB Period: Rilzabrutinib 400 mg TIDTotal
Mean30.0 ± 8.631.4 ± 7.330.2 ± 7.229.9 ± 8.630.3 ± 7.9
Weekly Itch Severity Score (ISS7)
Weekly Itch Severity Score (ISS7)(score on a scale)DB Period: Placebo TIDDB Period: Rilzabrutinib 400 mg QPM + PlaceboDB Period: Rilzabrutinib 400 mg BID + PlaceboDB Period: Rilzabrutinib 400 mg TIDTotal
Mean15.6 ± 4.216.5 ± 3.515.8 ± 3.715.9 ± 4.415.9 ± 4.0
08

Study locations

128 sites
  • Investigational Site Number : 0320006
    CABA, Buenos Aires C1055AAO, Argentina
  • Investigational Site Number :0320006
    CABA, Buenos Aires C1055AAO, Argentina
  • Investigational Site Number : 0320002
    CABA, Buenos Aires C1414AIF, Argentina
  • Investigational Site Number :0320002
    CABA, Buenos Aires C1414AIF, Argentina
  • Investigational Site Number : 0320004
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320005
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number :0320004
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number :0320005
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320003
    Rosario, Santa Fe Province S2000JKR, Argentina
  • Investigational Site Number :0320003
    Rosario, Santa Fe Province S2000JKR, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, C1121ABE, Argentina
  • Investigational Site Number :0320001
    Buenos Aires, C1121ABE, Argentina
  • Investigational Site Number :1240010
    Calgary, Alberta T2W 4X9, Canada
  • Investigational Site Number : 1240009
    Red Deer, Alberta T4P 1K4, Canada
  • Investigational Site Number :1240009
    Red Deer, Alberta T4P 1K4, Canada
  • Investigational Site Number : 1240005
    Toronto, Ontario M3B 3S6, Canada
  • Investigational Site Number :1240005
    Toronto, Ontario M3B 3S6, Canada
  • Investigational Site Number : 1240004
    Toronto, Ontario M5G 1E2, Canada
  • Investigational Site Number :1240004
    Toronto, Ontario M5G 1E2, Canada
  • Investigational Site Number : 1240006
    Montreal, Quebec H4A 3T2, Canada
  • Investigational Site Number :1240006
    Montreal, Quebec H4A 3T2, Canada
  • Investigational Site Number : 1240002
    Trois-Rivières, Quebec G8T 7A1, Canada
  • Investigational Site Number :1240002
    Trois-Rivières, Quebec G8T 7A1, Canada
  • Investigational Site Number : 1240003
    Québec, G1V 4W2, Canada
  • Investigational Site Number :1240003
    Québec, G1V 4W2, Canada
  • Investigational Site Number : 1520004
    Osorno, Los Lagos Region 5310644, Chile
  • Investigational Site Number :1520004
    Osorno, Los Lagos Region 5310644, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 7640881, Chile
  • Investigational Site Number :1520001
    Santiago, Reg Metropolitana de Santiago 7640881, Chile
  • Investigational Site Number :1520003
    Santiago, Reg Metropolitana de Santiago 7750000, Chile
  • Investigational Site Number : 1520002
    Santiago, Reg Metropolitana de Santiago 8420383, Chile
  • Investigational Site Number :1520002
    Santiago, Reg Metropolitana de Santiago, Chile
  • Investigational Site Number :2760002
    Berlin, 10117, Germany
  • Investigational Site Number : 2760002
    Berlin, 12200, Germany
  • Investigational Site Number : 2760001
    Dresden, 01307, Germany
  • Investigational Site Number :2760001
    Dresden, 01307, Germany
  • Investigational Site Number : 2760005
    Kiel, 24105, Germany
  • Investigational Site Number :2760005
    Kiel, 24105, Germany
  • Investigational Site Number : 2760004
    Mainz, 55131, Germany
  • Investigational Site Number :2760004
    Mainz, 55131, Germany
  • Investigational Site Number : 3000001
    Athens, 12462, Greece
  • Investigational Site Number :3000001
    Athens, 12462, Greece
  • Investigational Site Number : 3000002
    Athens, 16121, Greece
  • Investigational Site Number :3000002
    Athens, 16121, Greece
  • Investigational Site Number : 3000004
    N. Efkarpia, 56429, Greece
  • Investigational Site Number :3000004
    N. Efkarpia, 56429, Greece
  • Investigational Site Number : 3000003
    Thessaloniki, 56403, Greece
  • Investigational Site Number :3000003
    Thessaloniki, 56429, Greece
  • Investigational Site Number : 3800001
    Milan, Lombardy 20122, Italy
  • Investigational Site Number :3800001
    Milan, Lombardy 20122, Italy
  • Investigational Site Number :3800004
    Milan, Lombardy 20161, Italy
  • Investigational Site Number : 3800002
    Ancona, 60126, Italy
  • Investigational Site Number :3800002
    Ancona, 60126, Italy
  • Investigational Site Number : 3800005
    Catania, Italy
  • Investigational Site Number :3800005
    Catania, Italy
  • Investigational Site Number :3920004
    Nagoya, Aichi-ken 454-8509, Japan
  • Investigational Site Number : 3920005
    Chikushino-shi, Fukuoka 818-0083, Japan
  • Investigational Site Number :3920005
    Chikushino-shi, Fukuoka 818-0083, Japan
  • Investigational Site Number : 3920002
    Sapporo, Hokkaido 063-0005, Japan
  • Investigational Site Number :3920002
    Sapporo, Hokkaido 063-0005, Japan
  • Investigational Site Number : 3920001
    Sagamihara-shi, Kanagawa 252-0392, Japan
  • Investigational Site Number :3920001
    Sagamihara-shi, Kanagawa 252-0392, Japan
  • Investigational Site Number : 3920007
    Yokohama, Kanagawa 221-0825, Japan
  • Investigational Site Number :3920007
    Yokohama, Kanagawa 221-0825, Japan
  • Investigational Site Number : 3920006
    Izumo-shi, Shimane 693-8501, Japan
  • Investigational Site Number :3920006
    Izumo-shi, Shimane 693-8501, Japan
  • Investigational Site Number : 3920003
    Tachikawa-shi, Tokyo 190-0014, Japan
  • Investigational Site Number :3920003
    Tachikawa-shi, Tokyo 190-0014, Japan
  • Investigational Site Number : 3920004
    Nagoya, 454-8509, Japan
  • Investigational Site Number : 5280002
    Rotterdam, 3015 GD, Netherlands
  • Investigational Site Number :5280002
    Rotterdam, 3015 GD, Netherlands
  • Investigational Site Number : 5280001
    Utrecht, 3584 CX, Netherlands
  • Investigational Site Number :5280001
    Utrecht, 3584 CX, Netherlands
  • Investigational Site Number :6160007
    Wroclaw, Lower Silesian Voivodeship 50-088, Poland
  • Investigational Site Number : 6160007
    Wroclaw, Lower Silesian Voivodeship 53-673, Poland
  • Investigational Site Number : 6160001
    Gdansk, Pomeranian Voivodeship 80-214, Poland
  • Investigational Site Number :6160001
    Gdansk, Pomeranian Voivodeship 80-214, Poland
  • Investigational Site Number : 6160009
    Gdansk, Pomeranian Voivodeship 80-546, Poland
  • Investigational Site Number :6160009
    Gdansk, Pomeranian Voivodeship 80-546, Poland
  • Investigational Site Number : 6160008
    Krakow, 30-438, Poland
  • Investigational Site Number :6160008
    Krakow, 30-438, Poland
  • Investigational Site Number : 6160004
    Krakow, 31-011, Poland
  • Investigational Site Number :6160004
    Krakow, 31-011, Poland
  • Investigational Site Number :6160003
    Krakow, 31-302, Poland
  • Investigational Site Number : 6160005
    Lodz, 91-211, Poland
  • Investigational Site Number :6160005
    Lodz, 91-211, Poland
  • Investigational Site Number : 6160006
    Wroclaw, 50-566, Poland
  • Investigational Site Number :6160006
    Wroclaw, 50-566, Poland
  • Investigational Site Number : 6430005
    Moscow, 115522, Russia
  • Investigational Site Number :6430005
    Moscow, 115522, Russia
  • Investigational Site Number :6430006
    Moscow, 115522, Russia
  • Investigational Site Number : 6430002
    Moscow, 123182, Russia
  • Investigational Site Number :6430002
    Moscow, 123182, Russia
  • Investigational Site Number :6430003
    Saint Petersburg, 193231, Russia
  • Investigational Site Number :6430004
    Smolensk, 214006, Russia
  • Investigational Site Number : 6430001
    Stavropol, 355020, Russia
  • Investigational Site Number :6430001
    Stavropol, 355020, Russia
  • Investigational Site Number : 4100002
    Busan, Busan 49241, South Korea
  • Investigational Site Number :4100002
    Busan, Busan 602-739, South Korea
  • Investigational Site Number : 4100005
    Ansan-si, Gyeonggi-do 15355, South Korea

Showing the first 100 of 128 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gimenez-Arnau A, Ferrucci S, Ben-Shoshan M, Mikol V, Lucats L, Sun I, Mannent L, Gereige J. Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial. JAMA Dermatol. 2025 Jul 1;161(7):679-687. doi: 10.1001/jamadermatol.2025.0733. PubMed 40266575 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jul 2023, 19 months.

Results were first posted in Aug 2026, 3 years after primary completion. A results delay was requested in Jul 2024.

Of 31 phase 2 interventional studies under Chronic Urticaria, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 19 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2021
First posted
Nov 4, 2021
StartActual
Nov 24, 2021
Primary completionActual
Jul 19, 2023
CompletionActual
Apr 23, 2024
Results delay requested
Jul 18, 2024
Results first posted
Aug 6, 2026
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05107115
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 4, 2021
Start date
Nov 24, 2021
Primary completion
Jul 19, 2023
Completion
Apr 23, 2024
Results posted
Aug 6, 2026
Last update
Aug 6, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilzabrutinib

Start the discussion